Cargando…

Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?

INTRODUCTION: Anticoagulants such as argatroban and heparins (low-molecular-weight and unfractionated) play an immense role in preventing thromboembolic complications in clinical practice. Nevertheless, they can also have a negative effect on the immune system. This study is aimed at investigating t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bredthauer, Andre, Kopfmueller, Manuel, Gruber, Michael, Pfaehler, Sophie-Marie, Lehle, Karla, Petermichl, Walter, Seyfried, Timo, Bitzinger, Diane, Redel, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196999/ https://www.ncbi.nlm.nih.gov/pubmed/32405324 http://dx.doi.org/10.1155/2020/9783630

Ejemplares similares

Potential Impact of Local Anesthetics Inducing Granulocyte Arrest and Altering Immune Functions on Perioperative Outcome
por: Kolle, Gesche, et al.
Publicado: (2021)

Propofol Ameliorates Exaggerated Human Neutrophil Activation in a LPS Sepsis Model
por: Bredthauer, Andre, et al.
Publicado: (2021)

Polymorphonuclear Cell Chemotaxis and Suicidal NETosis: Simultaneous Observation Using fMLP, PMA, H7, and Live Cell Imaging
por: Pai, Delou, et al.
Publicado: (2020)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Bleeding complications after cardiac surgery, before anticoagulation start and then with argatroban or heparin in the early postoperative setting
por: Klingele, Matthias, et al.
Publicado: (2020)

Argatroban in the management of heparin-induced thrombocytopenia
por: Babuin, Luciano, et al.
Publicado: (2010)

Remote and Anesthetic-Induced Myocardial Preconditioning Is Preserved in Atherosclerotic LDL Receptor-/- Mice In Vivo
por: Petermichl, Walter, et al.
Publicado: (2021)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2021)

Anticoagulation with Argatroban in a Patient with Heparin-Induced Thrombocytopenia and Renal Insufficiency Undergoing Orthotopic Heart Transplantation
por: Green, Michael Stuart, et al.
Publicado: (2021)

Argatroban for an alternative anticoagulant in HIT during ECMO
por: Rougé, Alain, et al.
Publicado: (2017)

Butyrylcholinesterase as a perioperative complication marker in patients after transcatheter aortic valve implantation: a prospective observational study
por: Michels, Bernhard, et al.
Publicado: (2021)

Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass
por: Agarwal, Shvetank, et al.
Publicado: (2012)

In Vivo Effects of Neostigmine and Physostigmine on Neutrophil Functions and Evaluation of Acetylcholinesterase and Butyrylcholinesterase as Inflammatory Markers during Experimental Sepsis in Rats
por: Bitzinger, Diane I., et al.
Publicado: (2019)

Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
por: Grouzi, Elisavet
Publicado: (2014)

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
por: Tardy-Poncet, Brigitte, et al.
Publicado: (2015)

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
por: Ogawa, Yoshihiko, et al.
Publicado: (2020)

A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia
por: Deen, Imad U., et al.
Publicado: (2022)

Argatroban for anticoagulation of a blood salvage system - an ex-vivo study
por: Beiderlinden, Martin, et al.
Publicado: (2016)

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
por: Colarossi, Giorgia, et al.
Publicado: (2021)

Argatroban for heparin-induced thrombocytopenia therapy in ICU patients with sepsis or multiple organ dysfunction syndrome
por: Saugel, B, et al.
Publicado: (2009)

Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
por: Yokota, Yuya, et al.
Publicado: (2019)

Coagulation abnormalities in patients with COVID‐19 on venovenous ECLS increased risk for technical complications and support times but had no impact on survival
por: Lehle, Karla, et al.
Publicado: (2022)

Managing argatroban in heparin‐induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin‐induced thrombocytopenia
por: Marchetti, Matteo, et al.
Publicado: (2022)

A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra(®)) in Critically Ill Patients with Heparin Resistance †
por: Bachler, Mirjam, et al.
Publicado: (2020)

Adenosine A2A and A2B Receptor Substantially Attenuate Ischemia/Reperfusion Injury in Septic rat Hearts
por: Busse, Hendrik, et al.
Publicado: (2016)

Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study
por: Fisser, Christoph, et al.
Publicado: (2021)

Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2010)

Successful Management of Heparin-Induced Thrombocytopenia Using Argatroban in a Very Old Woman: A Case Report
por: Putot, A., et al.
Publicado: (2013)

Argatroban caused severe hypercholesterolaemia in a chronic haemodialysis patient with heparin-induced thrombocytopenia: an unreported adverse effect?
por: Nakagawa, Tetsuya
Publicado: (2008)

Accumulations of von Willebrand factor within ECMO oxygenators: Potential indicator of coagulation abnormalities in critically ill patients?
por: Steiger, Tamara, et al.
Publicado: (2019)

Bilirubin—A Possible Prognostic Mortality Marker for Patients with ECLS
por: Bunte, Sebastian, et al.
Publicado: (2020)

Comparison Between K(3)EDTA and Lithium Heparin as Anticoagulant to Isolate Bovine Granulocytes From Blood
por: Baien, Shima Hassan, et al.
Publicado: (2018)

Novel Monitoring and Dose Adjustment of Argatroban, a Direct Thrombin Inhibitor, to Maintain Therapeutic Anticoagulation in a Patient With Antiphospholipid Antibody Syndrome, Heparin-Induced Thrombocytopenia, and COVID-19 Pneumonia
por: Ryan, Christine E., et al.
Publicado: (2023)

Correction: Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2012)

Physiology of the ECL cells.
por: Håkanson, R., et al.
Publicado: (1998)

ECL cell morphology.
por: Chen, D., et al.
Publicado: (1998)

Life span of different extracorporeal membrane systems for severe respiratory failure in the clinical practice
por: Philipp, Alois, et al.
Publicado: (2018)

Argatroban Resistance and Successful Adjunctive Anticoagulation for Cerebral Venous Sinus Thrombosis With SERPINC1 Mutation: A Case Report
por: Ma, Hongrui, et al.
Publicado: (2023)

The biology and physiology of the ECL cell.
por: Håkanson, R., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_kt1u9ri9tetrqdc1erhbv3mff2